Anti-RANKL antibody (ab9957)
- Product nameAnti-RANKL antibodySee all RANKL primary antibodies ...
- DescriptionRabbit polyclonal to RANKL
- Tested applicationsICC/IF, ELISA, WB, IHC-P more details
- Species reactivityReacts with: Mouse, Human
Highly pure (>98%) recombinant hsRANK-L (human soluble receptor activator of NF-Kappa B Ligand)
- FormLyophilised:Reconstitute with 200µl of sterile water. Please note that if you receive this product in liquid form it has already been reconstituted as described and no further reconstitution is necessary.
- Storage instructionsStore at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze / thaw cycles.
- Storage bufferPBS, pH 7.4, no preservative, sterile filtered
- Concentration information loading...
- PurityImmunogen affinity purified
- Clonality Polyclonal
- Light chain typeunknown
- Research Areas
Our Abpromise guarantee covers the use of ab9957 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||ICC/IF: Use a concentration of 1 µg/ml.|
|ELISA||ELISA: Use at an assay dependent dilution. To detect hsRANK-L by direct ELISA (using 100µl/well antibody solution) a concentration of at least 0.5µg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with compatible secondary reagents, allows the detection of 0.2 - 0.4 ng/well of recombinant hsRANK-L.|
|WB||WB: Use a concentration of 1 µg/ml. Detects a band of approximately 37 kDa (predicted molecular weight: 35 kDa). To detect hsRANK-L by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hsRANK-L is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.|
|IHC-P||IHC-P: Use at an assay dependent dilution.|
- FunctionCytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy.
- Tissue specificityHighest in the peripheral lymph nodes, weak in spleen, peripheral blood Leukocytes, bone marrow, heart, placenta, skeletal muscle, stomach and thyroid.
- Involvement in diseaseDefects in TNFSF11 are the cause of osteopetrosis autosomal recessive type 2 (OPTB2) [MIM:259710]; also known as osteoclast-poor osteopetrosis. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Autosomal recessive osteopetrosis is usually associated with normal or elevated amount of non-functional osteoclasts. OPTB2 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development.
- Sequence similaritiesBelongs to the tumor necrosis factor family.
modificationsThe soluble form of isoform 1 derives from the membrane form by proteolytic processing (By similarity). The cleavage may be catalyzed by ADAM17.
- Cellular localizationCytoplasm; Secreted and Cell membrane.
- CD254 antibody
- hRANKL2 antibody
- ODF antibody
- OPGL antibody
- OPTB2 antibody
- Osteoclast differentiation factor antibody
- Osteoprotegerin ligand antibody
- RANKL antibody
- Receptor activator of nuclear factor kappa B ligand antibody
- Receptor activator of nuclear factor kappa-B ligand antibody
- sOdf antibody
- SOFA antibody
- TNF related activation induced cytokine antibody
- TNF-related activation-induced cytokine antibody
- TNF11_HUMAN antibody
- TNFSF 11 antibody
- TNFSF11 antibody
- TRANCE antibody
- Tumor necrosis factor (ligand) superfamily member 11 antibody
- Tumor necrosis factor ligand superfamily member 11 antibody
- Tumor necrosis factor ligand superfamily member 11, soluble form antibody
Anti-RANKL antibody images
ab9957 staining RANKL in human metastatic carcinoma of lymph nodes from breast cancer tissue by Immunohistochemistry (Formalin/PFA fixed paraffin-embedded sections). Tissue underwent heat mediated antigen retrieval in sodium citrate buffer (pH 6.0). The primary antibody was used at 0.25 ug/ml and incubated with sample at 4°C overnight. A HRP-labeled polymer detection system was used with a DAB chromogen.
ICC/IF image of ab9957 stained MCF7 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab9957, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
Anti-RANKL antibody (ab9957) at 1 µg/ml +
Spleen (Human) Tissue Lysate - adult normal tissue (ab29699) at 10 µg
Goat polyclonal Secondary Antibody to Rabbit IgG - H&L (HRP), pre-adsorbed at 1/3000 dilution
developed using the ECL technique
Performed under reducing conditions.
Predicted band size : 35 kDa
Observed band size : 37 kDa (why is the actual band size different from the predicted?)
Additional bands at : 72 kDa,76 kDa. We are unsure as to the identity of these extra bands.
Exposure time : 90 seconds
References for Anti-RANKL antibody (ab9957)
This product has been referenced in:
- Peng X et al. Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer. PLoS One 8:e58361 (2013). WB, IHC-P ; Human . Read more (PubMed: 23516466) »
- Mediero A et al. Adenosine A2A receptor activation prevents wear particle-induced osteolysis. Sci Transl Med 4:135ra65 (2012). IHC-P ; Mouse . Read more (PubMed: 22623741) »